In adult patients with sepsis, when is albumin indicated and what is the recommended dosing regimen?

Albumin Use in Sepsis

Albumin should be considered as an adjunctive fluid when patients with sepsis or septic shock require substantial amounts of crystalloids, though crystalloids remain the first-line choice for initial resuscitation. 1, 2, 1

Initial Fluid Resuscitation Strategy

• Start with crystalloids as the primary resuscitation fluid with an initial bolus of at least 30 mL/kg for patients with sepsis-induced tissue hypoperfusion and suspected hypovolemia 1, 2, 1
• Either balanced crystalloids or normal saline can be used, though balanced crystalloids may reduce major renal events 3
• Continue fluid administration using a fluid challenge technique as long as hemodynamic parameters continue to improve 1, 2, 1

When to Add Albumin

Albumin is indicated when patients require substantial amounts of crystalloids during initial resuscitation and subsequent volume replacement 1, 2, 1

Strength of Recommendation

• This is a weak recommendation with low quality evidence (Grade 2C in 2012-2016 guidelines) 1, 2, 1, 4
• The Surviving Sepsis Campaign 2021 maintained this weak recommendation with moderate quality evidence 5, 3

Dosing Considerations

For sepsis/septic shock:

• A portion of the initial 30 mL/kg fluid challenge may be albumin equivalent 1, 2, 1
• The FDA label suggests treatment with 25% albumin may offer therapeutic advantages in oncotic deficits or long-standing shock where treatment has been delayed 6
• Typical adult dosing ranges from 50-75 g daily for hypoproteinemia, though septic patients may require larger quantities 6

Concentration options:

• 20% albumin appears more beneficial than lower concentrations, particularly in septic shock 7
• High daily doses of albumin may improve survival specifically in septic shock patients 7
• 25% albumin (Plasbumin-25) is hyperoncotic and expands plasma volume 3-4 times the administered volume 6

Evidence Summary and Nuances

Mortality Outcomes

• The landmark ALBIOS trial (2014) showed no difference in 28-day or 90-day mortality between albumin plus crystalloids versus crystalloids alone in 1,818 severe sepsis patients 8
• Multiple meta-analyses show conflicting results: one 2011 meta-analysis suggested reduced mortality (OR 0.82) 9, while a 2024 meta-analysis found no mortality benefit 7
• Recent 2024 systematic reviews provide no strong evidence for albumin improving survival in general sepsis populations 5, 10

Physiologic Benefits Without Mortality Improvement

Despite lack of mortality benefit, albumin demonstrates several physiologic advantages:

• Lower total fluid volumes required (SAFE study: 3011 mL vs 3522 mL, p<0.001) 3
• Improved hemodynamics with higher mean arterial pressure 8
• Reduced vasopressor requirements and duration (ALBIOS: 3 vs 4 days, p=0.007) 3
• Lower cardiovascular SOFA scores 3
• A 2025 pilot trial showed less total fluid at 72 hours, fewer patients requiring vasopressors, and improved organ function 11

Important Caveats and Pitfalls

Avoid albumin in these situations:

• Do NOT use albumin for chronic hypoalbuminemia alone without acute illness 6, 10
• Do NOT use albumin as nutritional support in chronic conditions like cirrhosis, malabsorption, or malnutrition 6, 10
• Exercise caution with rapid infusion in hypoproteinemic patients (rate should not exceed 2 mL/min) to avoid circulatory overload and pulmonary edema 6
• A 2025 observational study using target trial emulation suggested early albumin may increase SA-AKI risk (relative difference 3.47%) without short-term survival benefit, though this requires clinical validation 12

Pediatric considerations:

• The FEAST trial showed increased mortality in African children with severe febrile illness receiving albumin or saline boluses compared to no bolus 5
• Albumin bolus resuscitation should be avoided in pediatric sepsis based on this high-quality evidence 5

Practical Algorithm

1. Begin with crystalloid resuscitation (30 mL/kg minimum) 1, 2, 1
2. Assess response using dynamic (pulse pressure variation, stroke volume variation) or static (arterial pressure, heart rate) hemodynamic variables 1, 2, 1
3. If requiring large crystalloid volumes (typically >30-50 mL/kg) with persistent hypoperfusion, consider adding albumin 1, 2, 1
4. Use 20-25% albumin at doses of 50-100g for adults, monitoring for fluid overload 6, 7
5. Target plasma albumin ≥2.5 g/dL if using albumin, though this target is based on physiologic rationale rather than outcome data 6

Cost-Benefit Consideration

The Surviving Sepsis Campaign explicitly notes that "lack of proven benefit and higher cost of albumin compared to crystalloid" supports the strong recommendation for crystalloids as first-line therapy 5. Given the weak evidence for mortality benefit, albumin should be reserved for patients with substantial crystalloid requirements where its fluid-sparing and hemodynamic effects may provide clinical value 1, 2, 1, 3.